GlassScriptPhysician profile
Jo P Deal
NPI 1003826272
$9,032.64
in general payments reported to CMS, 2019-2025
30 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $1,604 · 2021: $1,683 · 2022: $1,382 · 2023: $955 · 2024: $742 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,124.01 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,655.09 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Insmed, INC. | $1,456.42 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $762.78 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Gilead Sciences, INC. | $539.70 | 2019-2025 | Sunlenca |
| Csl Behring | $536.63 | 2019-2025 | Hizentra |
| Janssen Biotech, INC. | $476.41 | 2019-2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $444.87 | 2020-2024 | Hyqvia |
| Theratechnologies INC. | $408.48 | 2019-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Abbvie INC. | $362.90 | 2021-2024 | Dalvance, Teflaro |
| Paratek Pharmaceuticals, INC. | $332.50 | 2019-2025 | Nuzyra |
| Astellas Pharma US INC | $298.80 | 2019-2021 | |
| Grifols USA, LLC | $283.12 | 2019-2023 | Prolastin-C Liquid |
| Shire North American Group INC | $211.13 | 2019 | |
| Philips North America LLC | $210.63 | 2019-2023 | |
| Janssen Products, LP | $168.99 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $162.78 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $152.01 | 2019-2022 | |
| Allergan, INC. | $143.17 | 2019 | |
| Pfizer INC. | $99.49 | 2020-2025 | |
| Nabriva Therapeutics, Plc | $66.84 | 2020-2022 | |
| Melinta Therapeutics, LLC | $41.53 | 2019 | |
| Shionogi INC | $34.25 | 2021-2022 | |
| Baxter Healthcare | $33.91 | 2025 | Hillrom - Volara System, Tisseel |
| Invivyd INC | $33.78 | 2025 | Pemgarda |
| Emd Serono, INC. | $29.90 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.41 | 2025 | |
| Averitas Pharma INC. | $20.31 | 2023 | Qutenza |
| Eisai INC. | $15.22 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.34 | 2023 | Ultomiris |
| Grt US Holding, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jo Deal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.